Image

Image

BIMZELX: THE FIRST AND ONLY APPROVED DUAL SELECTIVE INHIBITOR OF IL-17A AND IL-17F FOR USE IN PSA AND AXSPA1–5
BLOCKING IL-17A AND IL-17F IN VITRO RESULTED IN SUPERIOR INHIBITION OF INFLAMMATORY RESPONSES VS BLOCKING IL-17A ALONE6
Image

Image

MORE INFORMATION
This content is intended for Healthcare Professionals only.
SE-P-BK-axSpA-2300028.
Date of preparation June 2023.